Ramonell Kimberly M, Yip Linwah
University of Pittsburgh, Pittsburgh, PA, USA.
Ann Surg Oncol. 2025 Apr;32(4):2323-2328. doi: 10.1245/s10434-024-16843-z. Epub 2025 Jan 16.
There has been remarkable growth in our understanding of the biologic behavior and molecular signature of thyroid malignancies, which has led to the introduction, application, and evolution of molecular testing of thyroid nodule FNA cytology. Next-generation sequencing molecular testing is an important, well-validated diagnostic tool for management of cytologically indeterminate thyroid nodules. It reduces unnecessary thyroid surgery for benign disease, avoiding associated surgical risks for the patient and reducing healthcare expenses. This article reviews the development and implementation of thyroid nodule cytologic classification and subsequent testing and how it has improved the diagnostic considerations in thyroid nodule and thyroid cancer management algorithms. The use of molecular testing as a prognostic tool is evolving and although the data are limited, they suggest a promising role in prognostication for oncologic outcomes. However, future studies are needed to further evaluate this.
我们对甲状腺恶性肿瘤的生物学行为和分子特征的理解有了显著进展,这促使甲状腺结节细针穿刺活检(FNA)细胞学的分子检测得以引入、应用和发展。新一代测序分子检测是管理细胞学结果不确定的甲状腺结节的一项重要且经过充分验证的诊断工具。它减少了因良性疾病而进行的不必要的甲状腺手术,避免了患者相关的手术风险,并降低了医疗费用。本文回顾了甲状腺结节细胞学分类以及后续检测的发展与实施情况,以及它如何改进了甲状腺结节和甲状腺癌管理算法中的诊断考量。分子检测作为一种预后工具的应用正在不断发展,尽管数据有限,但它们表明其在肿瘤学预后方面具有广阔前景。然而,未来还需要进一步的研究来对此进行评估。